Q32 Bio Inc.
Q32 Bio (Nasdaq: QTTB) is a clinical-stage biotechnology company developing biologics for autoimmune and inflammatory diseases. Its lead candidate, bempikibart, is a fully human monoclonal antibody designed to block IL-7 and TSLP signaling, and is being evaluated for severe and very severe alopecia areata, a disease… From the company’s description.
In fiscal 2025, Q32 Bio Inc. reported revenue of $53.74M and net income of $29.82M. Its operating margin was 31.5%, and operations used $33.54M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Q32 Bio Inc. does
In the company’s own words
Q32 Bio (Nasdaq: QTTB) is a clinical-stage biotechnology company developing biologics for autoimmune and inflammatory diseases. Its lead candidate, bempikibart, is a fully human monoclonal antibody designed to block IL-7 and TSLP signaling, and is being evaluated for severe and very severe alopecia areata, a disease that causes hair loss. The company completed Phase 2a trials in alopecia areata and atopic dermatitis and is conducting an open-label Phase 2a trial in alopecia areata; 33 patients enrolled in that trial, with dosing ongoing at year-end 2025. Q32 Bio has no products for sale and has not generated product revenue. It sold substantially all assets related to its ADX-097 complement-inhibitor program to Akebia Therapeutics in November 2025, while retaining rights to ADX-096 and other early-stage assets from its tissue-targeted complement-inhibitor platform. Its operations are focused on advancing bempikibart and evaluating options for the retained platform.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WALTHAM, MA
- Fiscal year end
- December
- CIK
- 1661998
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Q32 Bio Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Q32 Bio Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Q32 Bio Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Q32 Bio Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Q32 Bio Inc.'s last four quarterly filings that the numbers alone won't show?”